Now Playing
Opinion|Videos|May 1, 2024
Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera
Timothy Mok, PharmD, BCPS, BCOP, and Gabriela Hobbs, MD, introduce themselves and provide insights on the prevalence of hydroxyurea resistance or intolerance in patients with polycythemia vera (PV) and how it impacts treatment decisions and costs.
Advertisement
Episodes in this series
Advertisement
Related to this article
Elevated levels of immunoglobulin G (IgG) drive “inflammaging” processes that take a toll on skin tissue as people age, according to research results reported by Japanese researchers. Reducing IgG may mitigate the loss of collagen and elastin.
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
ProAct Chief Operating Offier Deborah Dempsey says plan sponsors still lack the data and visibility to know whether they were shorted on a 340B claim.
AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.
OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point drop in body mass index and improved mental health.
Yellow eyelid Xanthelasma signals hidden high cholesterol and cardiovascular disease risk, tripling heart attack and stroke odds; Negin Yavari, M.D., and her team urge screening.
Maladaptive coping at baseline raised relapse and symptom risk over 12 months in first episode psychosis, King's College London researchers found.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Navitus launches GLP-1 drug management programs
2
New AACR report has found U.S. Cancer death rate dropped 35% since 1991
3
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
4
Judi Health, Employers Health team up to launch new PBM solution
5